Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction

Wilhelmsen, 1986, The multifactor primary prevention trial in Goteborg, Sweden, Eur Heart J, 7, 279, 10.1093/oxfordjournals.eurheartj.a062065 Gheorghiade, 2003, Beta-blockers in chronic heart failure, Circulation, 107, 1570, 10.1161/01.CIR.0000065187.80707.18 Diaz, 2005, Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease, Eur Heart J, 26, 967, 10.1093/eurheartj/ehi190 Franciosa, 2004, Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry, Am Heart J, 148, 718, 10.1016/j.ahj.2004.04.006 Krum, 2006, Tolerability of beta-blockers in elderly patients with chronic heart failure: the COLA II study, Eur J Heart Fail, 8, 302, 10.1016/j.ejheart.2005.08.002 Ferrari, 2008, The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population, Cardiology, 110, 271, 10.1159/000112412 Dungen, 2011, Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial, Eur J Heart Fail, 13, 670, 10.1093/eurjhf/hfr020 2005, 1 Swedberg, 2010, Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study, Lancet, 376, 875, 10.1016/S0140-6736(10)61198-1 Fox, 2008, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial, Lancet, 372, 807, 10.1016/S0140-6736(08)61170-8 Fox, 2014, Ivabradine in stable coronary artery disease without clinical heart failure, N Engl J Med, 371, 1091, 10.1056/NEJMoa1406430 2015, 33 U.S. Food and Drug Administration. FDA approves Corlanor to treat heart failure [Web Page]. Silver Spring, MD: U.S. Food and Drug Administration; 2015 [updated 7/6/2015; cited 2015 10/9/2015]. Official Press Release]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm. U.S. Food and Drug Administration. Drug Trials Snapshot: CORLANOR Silver Spring, Maryland: U.S. Food and Drug Administration; 2015. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ucm446899.htm. Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control Clin Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J Natl Cancer Inst., 22, 719 Gavaghan, 2000, An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data, Pain, 85, 415, 10.1016/S0304-3959(99)00302-4 Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 Begg, 1994, Operating characteristics of a rank correlation test for publication bias, Biometrics, 50, 1088, 10.2307/2533446 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Duval, 2000, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis, Biometrics, 56, 455, 10.1111/j.0006-341X.2000.00455.x Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, Ann Intern Med, 151, 10.7326/0003-4819-151-4-200908180-00135 Fox, 2013, Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials, Eur Heart J, 34, 2263, 10.1093/eurheartj/eht101